Bank of Montreal
SRPT icon

Bank of Montreal’s Sarepta Therapeutics SRPT Stock Holding History

Bank of Montreal’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$152K – 4964
2019
Q2 		$152K Buy
+1,000
New +$122K ﹤0.01% 3079

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal's SRPT Position: Q1 2026 in Review

Bank of Montreal increased its Sarepta Therapeutics (SRPT) stake by 71% in Q1 2026, buying an estimated $207K and bringing the position to 25,815 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Bank of Montreal first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.8M in Q1 2022. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Bank of Montreal held 25,815 shares of Sarepta Therapeutics worth $562K as of Q1 2026.
  • Bank of Montreal bought 10,685 Sarepta Therapeutics shares in Q1 2026, an estimated $207K.
  • Sarepta Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #2339 holding.
  • Bank of Montreal first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Bank of Montreal's Sarepta Therapeutics position peaked at $37.8M in Q1 2022.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.